Amgen’s weight-loss drug, MariTide, showed up to 20% weight loss in a key trial, but its stock tumbled nearly 5% as results fell short of expectations. While the drug demonstrated potential in obesity treatment—with no weight-loss plateau observed—analysts had hoped for greater efficacy compared to Eli Lilly's Zepbound, which is achieving similar results with a more favorable side-effect profile. Despite concerns over higher dropout rates due to gastrointestinal issues, Amgen remains optimistic as it advances to phase three trials, exploring better dosing strategies.